Since LLY restructed their agreement with VRTX, VRTX has approximately doubled in share price
, while LLY has dropped significantly over the same period. On top of the 2x rise in PPS, VRTX has issued successful offerings, further raising their market cap.
You drag out a 3 year old piece of old LLY news in an attempt at undermining the prospects of VX-950 as a succsessful drug candidate? Good God, man.